**Question:** Which of the following is the mechanism of action of Fondaparinux?

A. Antithrombin, B. Heparin-induced thrombocytopenia, C. Factor Xa inhibition, D. Factor Xa and IIa activation

**Core Concept:**
Fondaparinux is a synthetic direct oral anticoagulant (DOAC) that belongs to a class of drugs known as Factor Xa inhibitors. Factor Xa is an enzyme involved in the intrinsic coagulation cascade, which is a series of enzymatic reactions that lead to the formation of thrombin (factor IIa), ultimately resulting in fibrin formation and blood clotting.

**Why the Correct Answer is Right:**
Fondaparinux specifically targets Factor Xa, an essential enzyme in the coagulation cascade. By inhibiting Factor Xa, it prevents the formation of thrombin (factor IIa), thereby inhibiting blood clot formation and preventing clotting.

**Why Each Wrong Option is Incorrect:**
A. Antithrombin: Antithrombin is a natural anticoagulant protein, not a mechanism of action for a drug.
B. Heparin-induced thrombocytopenia: This is a complication of heparin therapy, not related to the mechanism of action of Fondaparinux.
D. Factor Xa and IIa activation: While Fondaparinux does inhibit Factor Xa and IIa, the correct answer should focus on the mechanism of action of Fondaparinux itself, rather than the overall coagulation cascade.

**Clinical Pearl:**
Fondaparinux is a convenient option for anticoagulation therapy due to its direct, specific action on Factor Xa and lack of the need for monitoring blood levels. It is commonly used in the prevention and treatment of deep vein thrombosis, pulmonary embolism, and stroke associated with atrial fibrillation.

**Why the Correct Answer is Right:**
Fondaparinux acts as a direct inhibitor of Factor Xa, a key enzyme in the coagulation cascade. By inhibiting Factor Xa, Fondaparinux prevents the activation of thrombin (Factor IIa), which leads to the inhibition of blood clot formation and prevents clotting.

**Why Each Wrong Option is Incorrect:**
A. Antithrombin: Antithrombin is an anticoagulant protein that does not specifically target Factor Xa, making it an incorrect mechanism of action for Fondaparinux.
B. Heparin-induced thrombocytopenia: This is a complication associated with heparin therapy, not relevant to the mechanism of action of Fondaparinux.
C. Factor Xa and IIa activation: While Fondaparinux does inhibit Factor Xa and IIa, the correct answer should focus on the mechanism of action of Fondaparinux itself, rather than the overall coagulation cascade.